Literature DB >> 6717470

The role of deoxynucleoside triphosphate pools in the inhibition of DNA-excision repair and replication in human cells by hydroxyurea.

R D Snyder.   

Abstract

The effects of hydroxyurea (HU) on the DNA-excision repair process in human cells has been systematically examined. It is demonstrated that HU induces DNA single-strand break accumulation in a dose-dependent fashion in ultraviolet-irradiated and MMS-treated confluent but not log-phase fibroblasts and that these breaks are clearly the consequence of the inhibition by HU of the enzyme, ribonucleotide reductase. The breaks form rapidly, are stable for at least 10 h and largely disappear by 20 h. The production of these DNA-strand breaks is antagonized by a combined treatment of 10 microM deoxyadenosine, deoxycytidine and deoxyguanosine whereas thymidine potentiates strand-break formation at low HU concentrations. It is also confirmed that HU, while inhibiting replicative synthesis has no apparent inhibitory effect on unscheduled DNA synthesis (UDS) although the increased uptake of labeled DNA precursors into HU-treated cells makes it difficult to assess the actual effects on the repair-synthetic process. Analysis of the effects of HU on deoxynucleoside triphosphate pool levels and the demonstration of the failure of the HU block to replicative synthesis to be reversed by high (1 mM) concentrations of added deoxynucleosides lend support to the notion of compartmentalized dNTP pools for repair and replication.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6717470     DOI: 10.1016/0167-8817(84)90057-9

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  17 in total

1.  Posttreatment with sodium arsenite is coclastogenic in log phase but not in stationary phase.

Authors:  R Y Huang; K Y Jan; T C Lee
Journal:  Hum Genet       Date:  1987-02       Impact factor: 4.132

2.  Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model.

Authors:  K S Albain; L J Swinnen; L C Erickson; P J Stiff; R I Fisher
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Deoxyadenosine reverses hydroxyurea inhibition of vaccinia virus growth.

Authors:  M B Slabaugh; M L Howell; Y Wang; C K Mathews
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

Review 4.  How I use hydroxyurea to treat young patients with sickle cell anemia.

Authors:  Russell E Ware
Journal:  Blood       Date:  2010-03-11       Impact factor: 22.113

5.  Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters.

Authors:  Aisha L Walker; Ryan M Franke; Alex Sparreboom; Russell E Ware
Journal:  Exp Hematol       Date:  2011-01-21       Impact factor: 3.084

6.  Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage.

Authors:  Z Ping Lin; Yashang Lee; Fang Lin; Michael F Belcourt; Peining Li; Joseph G Cory; Peter M Glazer; Alan C Sartorelli
Journal:  Mol Pharmacol       Date:  2011-08-29       Impact factor: 4.436

7.  Activity of ribonucleotide reductase helps determine how cells repair DNA double strand breaks.

Authors:  Martin D Burkhalter; Steven A Roberts; Jody M Havener; Dale A Ramsden
Journal:  DNA Repair (Amst)       Date:  2009-08-26

8.  DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells.

Authors:  Martha Rodriguez Sandoval; Kumudha Balakrishnan; Rajyalakshmi Luthra; Michael Keating; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2013-07-29

9.  Cell cycle-dependent effects on deoxyribonucleotide and DNA labeling by nucleoside precursors in mammalian cells.

Authors:  J M Leeds; C K Mathews
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

10.  A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149).

Authors:  Lode J Swinnen; Cathryn Rankin; Hetty Carraway; Kathy S Albain; Jeannette J Townsend; George Thomas Budd; Julie A Kish; Saul E Rivkin; Deborah T Blumenthal
Journal:  J Neurooncol       Date:  2007-11-16       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.